Research programme: CLK3 targetting small molecule therapeutics - BioSplice Therapeutics [80901]
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Biosplice Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Clk dual-specificity kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 09 Jan 2025 Early research in Solid tumours in USA (PO) (BioSplice Therapeutics pipeline, January 2025)